Skip to main content
SpringerLink
Log in

Anagrelide is an effective platelet-lowering agent, but its role in the treatment of essential thrombocythaemia has yet to be fully determined

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Table III

Notes

  1. 1 The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 2006; 66(1): 111–31

    Article  PubMed  CAS  Google Scholar 

  2. Tefferi A, Silverstein MN. Treatment of polycythaemia vera and essential thrombocythaemia. Baillieres Clin Haematol 1998; 11: 769–85

    Article  PubMed  CAS  Google Scholar 

  3. Spencer CM, Brogden RN. Anagrelide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994 May; 47(6): 809–22

    Article  PubMed  CAS  Google Scholar 

  4. Michiels JJ, Berneman ZN, Schroyens W, et al. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004 Mar; 15(2): 67–84

    Article  PubMed  Google Scholar 

  5. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89(2): 215–32

    PubMed  CAS  Google Scholar 

  6. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 2005; 19: 243–52

    Article  PubMed  Google Scholar 

  7. Michiels JJ, Van Genderen PJJ. Essential thrombocythemia in childhood. Semin Thromb Hemost 1997; 23(3): 295–301

    Article  PubMed  CAS  Google Scholar 

  8. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005; 130: 153–65

    Article  PubMed  Google Scholar 

  9. Wang G, Franklin R, Hong Y, et al. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol 2005 Oct; 146(3): 324–32

    Article  PubMed  CAS  Google Scholar 

  10. Shire Pharmaceuticals Limited (UK). Xagrid 0.5mg hard capsule prescribing information [online]. Available from URL: http://www.emc.medicines.org.uk [Accesssed 2006 Jun 23]

  11. Steurer M, Gastl G, Jedrzejczak W-W, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004 Nov 15; 101(10): 2239–46

    Article  PubMed  CAS  Google Scholar 

  12. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353(1): 33–45

    Article  PubMed  CAS  Google Scholar 

  13. Mazur G, Wrobel T, Podolak-Dawidziak M, et al. Anagrelide in the treatment of thrombocythemia essential (ET) [in Polish]. Pol Arch Med Wewn 2004; 112: 1445–50

    PubMed  Google Scholar 

  14. Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 1999; 29: 29–35

    Article  PubMed  CAS  Google Scholar 

  15. Shire US Inc. Agrylin (anagrelide hydrochloride) capsules prescribing information. New York (NY), 2004 Dec

  16. Birgegard G, Bjorkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004; 89: 520–7

    PubMed  CAS  Google Scholar 

  17. Fruchtman SM, Petitt RM, Gilbert HS, et al. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005; 29(5): 481–91

    Article  PubMed  CAS  Google Scholar 

  18. AOP Orphan Pharmaceuticals AG. AOP 03-007 ANAHYDRET study [online]. Available from URL: http://www.anahydret.at [Accessed 2006 Jun 23]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anagrelide is an effective platelet-lowering agent, but its role in the treatment of essential thrombocythaemia has yet to be fully determined. Drugs Ther. Perspect 22, 1–5 (2006). https://doi.org/10.2165/00042310-200622110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622110-00001

Search

Navigation